

Stanford



Harlan Pinto

Associate Professor of Medicine (Oncology) at the Palo Alto Veterans Affairs Health Care System and, by courtesy of Otolaryngology - Head & Neck Surgery at the Stanford University Medical Center

Medicine - Oncology

CLINICAL OFFICES

- **Medical Oncology**

875 Blake Wilbur Dr Clinic B

MC 5820

Stanford, CA 94305

Tel (650) 498-7152

Fax (650) 725-9113

Bio

CLINICAL FOCUS

- Cancer > Head and Neck Cancer
- Medical Oncology
- Head and Neck Cancer
- Oncology

ACADEMIC APPOINTMENTS

- Associate Professor - Med Center Line, Medicine - Oncology
- Associate Professor - Med Center Line (By courtesy), Otolaryngology - Head & Neck Surgery Divisions
- Member, Stanford Cancer Institute

PROFESSIONAL EDUCATION

- Residency: Massachusetts General Hospital Internal Medicine Residency (1986) MA
- Fellowship: Stanford University School of Medicine Registrar (1991) CA
- Medical Education: Yale School Of Medicine Office of Student Affairs (1983) CT
- Internship: Massachusetts General Hospital (1984) MA
- Board Certification: Medical Oncology, American Board of Internal Medicine (1991)
- Board Certification: Internal Medicine, American Board of Internal Medicine (1986)

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Clinical investigations focus on head and neck cancer with a particular interest in combined modality therapy. Through the Stanford University Head and Neck Tumor Board, clinical trials are conducted which involve all aspects of care for patients with head and neck cancer. The clinical research program includes translation of preclinical work performed in the Radiobiology Section at Stanford, new drug development, the development of novel combination therapy, chemoprevention, and the integration of biological response modifiers into combined modality treatment.

As a member of Stanford's Eastern Cooperative Oncology Group trials effort, Dr. Pinto is involved in the implementation and development of a variety of clinical trials at Stanford and the Palo Alto Veterans Affairs Medical Center.

CLINICAL TRIALS

- Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers, Recruiting
- A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations, Not Recruiting
- A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer, Not Recruiting
- A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma, Not Recruiting
- A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck, Not Recruiting
- Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia, Not Recruiting
- Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms, Not Recruiting
- BIBW 2992 (Afatinib) in Head & Neck Cancer, Not Recruiting
- Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer, Not Recruiting
- Biopsy of Human Tumors for Cancer Stem Cell Characterization: a Feasibility Study, Not Recruiting
- Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery, Not Recruiting
- Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer, Not Recruiting
- Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Not Recruiting
- Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery, Not Recruiting
- Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck, Not Recruiting
- Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma, Not Recruiting
- Compassionate Use Trial for Unresectable Melanoma With Ipilimumab, Not Recruiting
- Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma, Not Recruiting
- Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery, Not Recruiting
- Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer, Not Recruiting
- Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer, Not Recruiting
- High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma, Not Recruiting
- Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer, Not Recruiting
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery, Not Recruiting
- Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery, Not Recruiting
- Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy, Not Recruiting

- Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer, Not Recruiting
- Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer, Not Recruiting
- Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer, Not Recruiting
- Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck, Not Recruiting
- Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer, Not Recruiting
- Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer, Not Recruiting
- Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer, Not Recruiting
- Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma, Not Recruiting
- Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma, Not Recruiting
- Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma, Not Recruiting
- Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma, Not Recruiting
- S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma, Not Recruiting
- Selenium in Preventing Tumor Growth in Patients With Previously Resected Stage I Non-small Cell Lung Cancer, Not Recruiting
- Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer, Not Recruiting
- Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma, Not Recruiting
- Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery, Not Recruiting
- Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer, Not Recruiting
- Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma, Not Recruiting
- Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN), Not Recruiting

Publications

PUBLICATIONS

- **Head and Neck Cancers, Version 1.2015.** *Journal of the National Comprehensive Cancer Network*
Pfister, D. G., Spencer, S., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Foote, R. L., Gilbert, J., Gillison, et al
2015; 13 (7): 847-856
- **Head and Neck Cancers, Version 1.2015 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Pfister, D. G., Spencer, S., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Foote, R. L., Gilbert, J., Gillison, et al
2015; 13 (7): 847-856
- **Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.** *Head & neck*
Tang, C., Chan, C., Jiang, W., Murphy, J. D., von Eyben, R., Colevas, A. D., Pinto, H., Lee-Enriquez, N., Kong, C., Le, Q.
2015; 37 (3): 386-392
- **Head and Neck Cancers, Version 2.2014** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Pfister, D. G., Spencer, S., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Gilbert, J., Gillison, M. L., Haddad, et al
2014; 12 (10): 1454-1487
- **Head and Neck Cancers, Version 2.2013 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Pfister, D. G., Ang, K., Brizel, D. M., Burtness, B. A., Busse, P. M., Caudell, J. J., Cmelak, A. J., Colevas, A. D., Dunphy, F., Eisele, D. W., Gilbert, J., Gillison, M. L., Haddad, et al

2013; 11 (8): 917-923

- **Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence.** *Cancer*
Ho, A. S., Tsao, G. J., Chen, F. W., Shen, T., Kaplan, M. J., Colevas, A. D., Fischbein, N. J., Quon, A., Le, Q., Pinto, H. A., Fee, W. E., Sunwoo, J. B., Sirjani, et al
2013; 119 (7): 1349-1356
- **A Planned Neck Dissection Is Not Necessary in All Patients With N2-3 Head-and-Neck Cancer After Sequential Chemoradiotherapy** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Soltys, S. G., Choi, C. Y., Fee, W. E., Pinto, H. A., Le, Q.
2012; 83 (3): 994-999
- **Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer** *GASTROINTESTINAL ENDOSCOPY*
Chang, K. J., Reid, T., Senzer, N., Swisher, S., Pinto, H., Hanna, N., Chak, A., Soetikno, R.
2012; 75 (6): 1139-?
- **Head and Neck Cancers** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Pfister, D. G., Ang, K., Brizel, D. M., Burtness, B. A., Cmelak, A. J., Colevas, D., Dunphy, F., Eisele, D. W., Gilbert, J., Gillison, M. L., Haddad, R. I., Haughey, B. H., Hicks, et al
2011; 9 (6): 596-649
- **INTENSITY-MODULATED RADIOTHERAPY FOR LOCALLY ADVANCED CANCERS OF THE LARYNX AND HYPOPHARYNX** *HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK*
Daly, M. E., Le, Q., Jain, A. K., Maxim, P. G., Hsu, A., Loo, B. W., Kaplan, M. J., Fischbein, N. J., Colevas, A. D., Pinto, H., Chang, D. T.
2011; 33 (1): 103-111
- **INTENSITY-MODULATED RADIOTHERAPY IN THE TREATMENT OF OROPHARYNGEAL CANCER: CLINICAL OUTCOMES AND PATTERNS OF FAILURE** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Daly, M. E., Le, Q., Maxim, P. G., Loo, B. W., Kaplan, M. J., Fischbein, N. J., Pinto, H., Chang, D. T.
2010; 76 (5): 1339-1346
- **In vivo H-1 magnetic resonance spectroscopy of lactate in patients with Stage IV head and neck squamous cell carcinoma** *49th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology (ASTRO)*
Le, Q., Koong, A., Lieskovsky, Y. Y., Narasimhan, B., Graves, E., Pinto, H., Brown, J. M., Spielman, D.
ELSEVIER SCIENCE INC.2008: 1151-57
- **Excellent local control with stereotactic radiotherapy boost after external beam radiotherapy in patients with nasopharyngeal carcinoma** *87th Annual Meeting of the American-Radium-Society*
Hara, W., Loo, B. W., Goffinet, D. R., Chang, S. D., Adler, J. R., Pinto, H. A., Fee, W. E., Kaplan, M. J., Fischbein, N. J., Le, Q.
ELSEVIER SCIENCE INC.2008: 393-400
- **Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial** *JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Fakhry, C., Westra, W. H., Cmelak, S. L., Ridge, J. A., Pinto, H., Forastiere, A., Gillison, M. L.
2008; 100 (4): 261-269
- **Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: Results of Eastern Cooperative Oncology Group study E2399** *42nd Annual Meeting of the American-Society-of-Clinical-Oncology*
Cmelak, A. J., Li, S., Goldwasser, M. A., Murphy, B., Cannon, M., Pinto, H., Rosenthal, D. I., Gillison, M., Forastiere, A. A.
AMER SOC CLINICAL ONCOLOGY.2007: 3971-77
- **Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma** *45th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology (ASTRO)*
Daly, M. E., Lieskovsky, Y., Pawlicki, T., Yau, J., Pinto, H., Kaplan, M., Fee, W. E., Koong, A., Goffinet, D. R., Xing, L., Le, Q.
JOHN WILEY & SONS INC.2007: 211-20
- **Clinical role of F-18-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma** *JOURNAL OF NUCLEAR MEDICINE*
Quon, A., Fischbein, N. J., McDougall, I. R., Le, Q., Loo, B. W., Pinto, H., Kaplan, M. J.
2007; 48: 58S-67S

- **Plasma osteopontin is an independent prognostic marker for head and neck cancers** *41st Annual Meeting of the American-Society-of-Clinical-Oncology*
Petrik, D., Lavori, P. W., Cao, H., Zhu, Y., Wong, P., Christofferson, E., Kaplan, M. J., Pinto, H. A., Sutphin, P., Koong, A. C., Giaccia, A. J., Le, Q.
AMER SOC CLINICAL ONCOLOGY.2006: 5291-97
- **Advanced-staged tonsillar squamous carcinoma: Organ preservation versus surgical management of the primary site** *90th Scientific Assembly and Annual Meeting of the Radiological-Society-of-North-America*
Shirazi, H. A., Sivanandan, R., Goode, R., Fee, W. E., Kaplan, M. J., Pinto, H. A., Goffinet, D. R., Le, Q.
JOHN WILEY & SONS INC.2006: 587-94
- **Mature results from a randomized phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable stage IV head and neck squamous cell carcinomas** *CANCER*
Le, Q. T., Taira, A. I., Budenz, S., Dorie, M. J., Goffinet, D. R., Fee, W. E., Goode, R., Bloch, D., Koong, A., Brown, J. M., Pinto, H. A.
2006; 106 (9): 1940-1949
- **Phase II trial of taxol in salivary gland malignancies (E1394): A trial of the Eastern Cooperative Oncology Group** *HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK*
Gilbert, J., Li, Y., Pinto, H. A., JENNINGS, T., Kies, M. S., Silverman, P., Forastiere, A. A.
2006; 28 (3): 197-204
- **Positron-emission tomography for surveillance of head and neck cancer** *LARYNGOSCOPE*
Ryan, W. R., Fee, W. E., Le, Q. T., Pinto, H. A.
2005; 115 (4): 645-650
- **Long-term results of 100 consecutive comprehensive neck dissections - Implications for selective neck dissections** *ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY*
Sivanandan, R., Kaplan, M. J., Lee, K. J., Lebl, D., PINTO, H., Le, Q. T., Goffinet, D. R., Fee, W. E.
2004; 130 (12): 1369-1373
- **Phase II double-blind randomized study comparing oral aloe vera versus placebo to prevent radiation-related mucositis in patients with head-and-neck neoplasms** *39th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Su, C. K., Mehta, V., Ravikumar, L., Shah, R., PINTO, H., Halpern, J., Koong, A., Goffinet, D., Le, Q. T.
ELSEVIER SCIENCE INC.2004: 171-77
- **Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma** *44th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology*
Le, Q. T., Tate, D., Koong, A., Gibbs, I. C., Chang, S. D., Adler, J. R., Pinto, H. A., Terris, D. J., Fee, W. E., Goffinet, D. R.
ELSEVIER SCIENCE INC.2003: 1046-54
- **Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients** *Annual Meeting on Radiation Research*
Le, Q. T., Kovacs, M. S., Dorie, M. J., Koong, A., Terris, D. J., Pinto, H. A., Goffinet, D. R., Nowels, K., Bloch, D., Brown, J. M.
ELSEVIER SCIENCE INC.2003: 375-83
- **Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas** *CLINICAL CANCER RESEARCH*
Le, Q. T., Sutphin, P. D., Raychaudhuri, S., Yu, S. C., Terris, D. J., Lin, H. S., Lum, B., Pinto, H. A., Koong, A. C., Giaccia, A. J.
2003; 9 (1): 59-67
- **Estimating DNA repair by sequential evaluation of head and neck tumor radiation sensitivity using the comet assay** *5th International Conference on Head and Neck Cancer of the International-Society-of-Head-Neck-Cancer*
Terris, D. J., Ho, E. Y., Ibrahim, H. Z., Dorie, M. J., Kovacs, M. S., Le, Q. T., Koong, A. C., Pinto, H. A., Brown, J. M.
AMER MEDICAL ASSOC.2002: 698-702
- **Physician perspectives on increasing minorities in cancer clinical trials: An Eastern Cooperative Oncology Group (ECOG) initiative** *Workshop on Participation of Minorities and Women in Clinical Cancer Research*
Pinto, H. A., McCaskill-Stevens, W., Wolfe, P., Marcus, A. C.
ELSEVIER SCIENCE INC.2000: S78-S84
- **In vivo H-1 MR spectroscopy of human head and neck lymph node metastasis and comparison with oxygen tension measurements** *AMERICAN JOURNAL OF NEURORADIOLOGY*
Star-Lack, J. M., Adalsteinsson, E., Adam, M. F., Terris, D. J., Pinto, H. A., Brown, J. M., Spielman, D. M.
2000; 21 (1): 183-193

- **DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.** *Neoplasia*
Dorie, M. J., Kovacs, M. S., Gabalski, E. C., Adam, M., Le, Q. T., Bloch, D. A., Pinto, H. A., Terris, D. J., Brown, J. M.
1999; 1 (5): 461-467
- **Stereotactic radiosurgical boost following radiotherapy in primary nasopharyngeal carcinoma: Impact on local control** *39th Annual Meeting of ASTRO*
Tate, D. J., Adler, J. R., Chang, S. D., Marquez, S., Eulau, S. M., Fee, W. E., PINTO, H., Goffinet, D. R.
ELSEVIER SCIENCE INC.1999: 915-21
- **Tissue oxygen distribution in head and neck cancer patients** *HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK*
Adam, M. F., Gabalski, E. C., Bloch, D. A., Oehlert, J. W., Brown, J. M., Elsaid, A. A., Pinto, H. A., Terris, D. J.
1999; 21 (2): 146-153
- **Recruiting minority cancer patients into cancer clinical trials: A pilot project involving the Eastern Cooperative Oncology Group and the National Medical Association** *JOURNAL OF CLINICAL ONCOLOGY*
McCaskill-Stevens, W., PINTO, H., Marcus, A. C., Comis, R., Morgan, R., Plomer, K., Schoentgen, S.
1999; 17 (3): 1029-1039
- **Pretreatment and midtreatment measurement of oxygen tension levels in head and neck cancers** *LARYNGOSCOPE*
Gabalski, E. C., Adam, M., PINTO, H., Brown, J. M., Bloch, D. A., Terris, D. J.
1998; 108 (12): 1856-1860
- **Management of the clinically positive neck in organ preservation for advanced head and neck cancer** *44th Annual Meeting of the Society-of-Head-and-Neck-Surgeons*
Dagum, P., Pinto, H. A., Newman, J. P., Higgins, J. P., Terris, D. J., Goffinet, D. R., Fee, W. E.
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC.1998: 448-52
- **Surgical morbidity of neck dissection after chemoradiotherapy in advanced head and neck cancer** *Western Section Meeting of the American-Laryngological-Rhinological-and-Otological-Society*
Newman, J. P., Terris, D. J., Pinto, H. A., Fee, W. E., Goode, R. L., Goffinet, D. R.
ANNALS PUBL CO.1997: 117-22
- **Adjuvant and neoadjuvant treatment of head and neck cancers: The next chapter** *SEMINARS IN ONCOLOGY*
Jacobs, C., PINTO, H.
1995; 22 (6): 540-552
- **Distant metastases from head and neck squamous cancer: the role of adjuvant chemotherapy.** *Cancer treatment and research*
Pinto, H. A., Jacobs, C.
1995; 74: 243-262
- **Head and neck cancers.** *Macdonald JS, Haller DG, Mayer RJ (eds), Manual of Oncologic Therapeutics Third Edition. J.B. Lippincott, Philadelphia*
Jacobs C, Pinto HA.
1995: 162-169.
- **Head and neck cancer - combined modality therapy and chemotherapy.** : *Brian MC and Carbone PP (eds), Current Therapy in Hematology-Oncology. Mosby, St. Louis*
Pinto HA, Jacobs C.
1995
- **CHEMOTHERAPY FOR RECURRENT AND METASTATIC HEAD AND NECK-CANCER** *HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA*
Pinto, H. A., Jacobs, C.
1991; 5 (4): 667-686